Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease - PubMed (original) (raw)

. 1995 Mar;273(12):942-7.

Affiliations

PMID: 7884953

Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease

G W Small et al. JAMA. 1995 Mar.

Abstract

Objective: Cerebral parietal hypometabolism and left-right asymmetry occur early in the course of Alzheimer disease (AD), and the apolipoprotein E type 4 allele (APOE epsilon 4) is a risk factor for familial AD. To determine if APOE epsilon 4 is associated with lowered brain function in nondemented relatives at risk for familial AD, we studied 12 relatives with APOE epsilon 4 and 19 relatives without APOE epsilon 4. We also compared them with seven patients with probable AD.

Design: After grouping subjects according to diagnosis and genotype, brain function measures were compared among groups.

Setting: University medical center.

Patients: At risk subjects had mild memory complaints, normal cognitive performance, and at least two relatives with AD. Subjects with APOE epsilon 4 did not differ from those without APOE epsilon 4 in mean age at examination (56.4 vs 55.5 years) or in neuropsychological performance (mean Mini-Mental State Examination score, 28.8 vs 29.3).

Main outcome measures: Cerebral glucose metabolism was measured using positron emission tomography and fludeoxyglucose F 18.

Results: Parietal metabolism was significantly lower and left-right parietal asymmetry was significantly higher in at-risk subjects with APOE epsilon 4 compared with those without APOE epsilon 4. Patients with dementia had significantly lower parietal metabolism than did at-risk subjects with APOE epsilon 4.

Conclusions: These results suggest that the inheritance of APOE epsilon 4 is associated with reduced cerebral parietal metabolism and increased asymmetry in non-demented relatives at risk for probable AD. Longitudinal study will determine if glucose metabolic measures provide a means to monitor experimental treatment responses during the early phases of the disorder.

PubMed Disclaimer

Cited by

Aberrant White Matter Microstructure as a Potential Diagnostic Marker in Alzheimer's Disease by Automated Fiber Quantification.
Chen H, Sheng X, Qin R, Luo C, Li M, Liu R, Zhang B, Xu Y, Zhao H, Bai F. Chen H, et al. Front Neurosci. 2020 Sep 24;14:570123. doi: 10.3389/fnins.2020.570123. eCollection 2020. Front Neurosci. 2020. PMID: 33071742 Free PMC article.
Assessment of Alzheimer's disease risk with functional magnetic resonance imaging: an arterial spin labeling study.
Bangen KJ, Restom K, Liu TT, Wierenga CE, Jak AJ, Salmon DP, Bondi MW. Bangen KJ, et al. J Alzheimers Dis. 2012;31 Suppl 3(0):S59-74. doi: 10.3233/JAD-2012-120292. J Alzheimers Dis. 2012. PMID: 22531427 Free PMC article.
When Does Alzheimer's Disease Really Start? The Role of Biomarkers.
Lloret A, Esteve D, Lloret MA, Cervera-Ferri A, Lopez B, Nepomuceno M, Monllor P. Lloret A, et al. Int J Mol Sci. 2019 Nov 6;20(22):5536. doi: 10.3390/ijms20225536. Int J Mol Sci. 2019. PMID: 31698826 Free PMC article. Review.
Amyloid load in nondemented brains correlates with APOE e4.
Caselli RJ, Walker D, Sue L, Sabbagh M, Beach T. Caselli RJ, et al. Neurosci Lett. 2010 Apr 12;473(3):168-71. doi: 10.1016/j.neulet.2010.02.016. Epub 2010 Feb 12. Neurosci Lett. 2010. PMID: 20153809 Free PMC article.
The cerebrocortical areas in normal brain aging and in Alzheimer's disease: noticeable differences in the lipid peroxidation level and in antioxidant defense.
Karelson E, Bogdanovic N, Garlind A, Winblad B, Zilmer K, Kullisaar T, Vihalemm T, Kairane C, Zilmer M. Karelson E, et al. Neurochem Res. 2001 Apr;26(4):353-61. doi: 10.1023/a:1010942929678. Neurochem Res. 2001. PMID: 11495345

Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease - PubMed (original) (raw)